Abstract:Objective To explore associated risk factors of clopidogrel resistance in patients with coronary artery disease(CAD) after percutaneous coronary intervention(PCI). Methods 108 CAD patients underwent PCI. They were treated with oral aspirin 300 mg and clopidogrel 300 mg before and aspirin 100 mg and clopidogrel 75 mg daily after PCI. Thrombelastography was performed at the third day post PCI. The patients were divided into clopidogrel resistance group and non- clopidogrel resistance group based on adenosine diphosphate (ADP) induced platelet aggregation inhibition < or > 30%. The histories of diabetes, hypertension and smoking, serum lipid, platelet count, fast blood sugar and C- reaction protein were analyzed and compared between groups. Results Clopidogrel resistance occurred in 42 cases. There was significant difference of the history of smoking and diabetes,and platelet counts between the two groups (al P<0.05). Logistic regression analysis showed that no- smoking history(OR=4.707, 95%CI=1.796~12.316, P<0.01), history of diabetes (OR=3.625, 95%CI=1.363~9.641, P<0.05), and high platelet counts(OR=0.990, 95%CI=0.983~0.997, P<0.01) were independent risk factors of clopidogrel resistance. Conclusion The incidence of clopidogrel resistance is higher in CAD patients after PCI. No- smoking history, diabetes and high platelet counts are risk factors of clopidogrel resistance.

Progress in Research into Aspirin and Clopidogrel Resistance

Progress in Research to Related Factors for Clopidogrel Resistance

Progress of Research on Clopidogrel Resistance in the Patients with Acute Coronary Syndrome

Mechanisms of Aspirin Resistance

Aspirin Resistance in the Elder Cardio-Cerebral-Vascular Diseases Patients

ADVANCES IN RESEARCH AND PREVENTION OF ASPIRIN RESISTANCE

Aspirin and clopidogrel resistance

Advances on the Causes and Strategies of Clopitlogrel Resistance

Aspirin and clopidogrel resistance: an emerging clinical entity

Clinical analysis of clopidogrel resistance in patients with coronary heart disease after percutaneous coronary intervention

Clopidogrel Resistance and the Prevention and Treatment of Stroke

The clinical and laboratory research on aspirin resistance in cardiovascular and cerebrovascular patients

Antiplatelet agent resistance and prevention and treatment of stroke

Research Progress of Aspirin Resistance in Diabetic Statue

Aspirin Resistance and Other Aspirin-Related Concerns

Consideration and Implication of Clopidogrel Resistance in Era of Percutaneous Coronary Intervention: core recognition and benefit improvement

Aspirin Resistance and Its Clinical Strategies

Research progress of antiplatelet drug "nonresponder"

Study on Genetic Factors of Clopidogrel Resistance

Drug Resistance and Strategies in Antiplatelet Therapy for the Management of Ischemic Stroke

The research progress of CYP2C19 gene polymorphism and clopidogrel resistance